News | September 15, 2009

Ontario Insuring PET for Cancer, Cardiac Imaging a Boon to Manufacturers


September 15, 2009 - Positron Corp. announced that the Ministry of Health and Long Term Care of Ontario, Canada is making positron emission tomography (PET) scanning a publicly insured health service available to cancer and cardiac patients under conditions where PET scans have been proven to be clinically effective. The Ministry of Health and Long Term Care (MOHLTC) has adopted an evidence-based approach to the introduction of PET imaging in the province for certain cancer and cardiac indications.

“Ontario, the largest province in Canada, introducing PET into their health system represents a significant opportunity for Positron to offer a cost effective general purpose scanner into a large socialized network,” said Joe Oliverio, chief technical officer of Positron. “We believe that the market for Positron’s Attrius PET scanner is potentially hundreds of units in a relatively short period of time. Health Canada’s approval of PET is further evidence that PET is the future of nuclear medicine. Positron plans to focus on marketing and selling its PET product throughout all Canadian provinces and estimates the entire market potential to be approximately 1,000 scanners.”

For more information: www.positron.com


Related Content

News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Home June 18, 2024
Home
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Home June 14, 2024
Home
News | PET Imaging

October 5, 2023 — Jubilant DraxImage Inc., a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an ...

Home October 05, 2023
Home
News | PET Imaging

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Home December 01, 2022
Home
News | PET Imaging

September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of ...

Home September 14, 2022
Home
News | PET Imaging

August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron ...

Home August 25, 2022
Home
News | PET Imaging

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Home June 15, 2022
Home
Technology | PET Imaging

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ...

Home December 05, 2018
Home
News | PET Imaging

July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new ...

Home July 17, 2018
Home
News | PET Imaging

July 7, 2017 — Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are ...

Home July 07, 2017
Home
Subscribe Now